TISSIUM announced a €60 million financing package to support its commercial and clinical activities, pipeline development, and platform expansion. The financing package includes a completed €30 million Series D2 financing and a financing facility of up to €30 million from the European Investment Bank.
TISSIUM is a medical technology company pioneering biomorphic programmable polymers for tissue reconstruction. The company is based in Paris and Cambridge, Massachusetts, and also has a manufacturing site in Roncq, France.
The financing follows a significant period for TISSIUM, including FDA marketing authorization for COAPTIUM CONNECT, the company’s first commercial product. The milestone also supports TISSIUM’s entry into the U.S. market and continued progress across its pipeline of products for atraumatic nerve repair, atraumatic hernia repair, and cardiovascular applications.
The €30 million Series D2 financing was completed at the end of 2025 with participation from leading new and existing international investors, including investors in the United States. TISSIUM said the round strengthens its shareholder base and provides capital to support commercial and clinical activities.
The company also secured a financing facility of up to €30 million from the European Investment Bank. The facility aligns with the objectives of InvestEU, which supports research, innovation, and the development of transformative healthcare technologies across Europe.
The European Investment Bank facility is available in three €10 million tranches tied to commercial, clinical, and financing milestones. The structure combines dilutive and venture debt financing. TISSIUM expects to draw the first €10 million tranche before the end of June 2026.
TISSIUM said the combined financing package gives the company strategic flexibility as it rolls out COAPTIUM CONNECT commercially in the United States, advances multiple clinical programs across surgical applications, and continues expanding its proprietary biomorphic polymer platform.
The company’s platform consists of fully biosynthetic, biomorphic, programmable, elastomeric polymers designed to address unmet needs in atraumatic tissue repair and reconstruction. TISSIUM’s pipeline includes one commercial product and six products in development across three core areas: atraumatic sutureless nerve repair, atraumatic hernia repair, and cardiovascular sealants.
Founded in 2013, TISSIUM is built on research and intellectual property originating from the laboratories of Professor Robert Langer at MIT and Professor Jeffrey M. Karp at Brigham and Women’s Hospital.
KEY QUOTES:
“This financing marks an important milestone in TISSIUM’s evolution. Following the FDA marketing authorization of COAPTIUM CONNECT, we are now executing on our transition into a commercial-stage MedTech company while continuing to advance a differentiated pipeline built on the same underlying biomorphic polymer platform.”
“The support of both leading international investors and the European Investment Bank reflects confidence in our technology, our strategy and our ability to bring meaningful innovation to patients. This financing provides the capital and strategic flexibility required to accelerate commercial execution while continuing to invest in the future growth of our platform.”
Christophe Bancel, CEO and Co-Founder of TISSIUM
